2024
Phase II trial of regorafenib in metastatic medullary thyroid carcinoma (MTC) and radioactive iodine refractory differentiated thyroid carcinoma (RAIR DTC).
Sehgal K, Shi R, Pappa T, Min J, Oakley L, ONeill A, Dennis M, Deshpande H, Haddad R, Lorch J. Phase II trial of regorafenib in metastatic medullary thyroid carcinoma (MTC) and radioactive iodine refractory differentiated thyroid carcinoma (RAIR DTC). Journal Of Clinical Oncology 2024, 42: 6109-6109. DOI: 10.1200/jco.2024.42.16_suppl.6109.Peer-Reviewed Original ResearchMetastatic medullary thyroid carcinomaTreatment-related adverse eventsProgression-free survivalRAIR-DTCProgression-freeOverall survivalClinical trialsMedian progression-free survivalCycle 2 onwardsMedian overall survivalPhase II clinical trialMedullary thyroid carcinomaPhase II trialMulti-kinase inhibitorII clinical trialsSimon's two-stage designRECIST v1.1Systemic therapyTolerated doseStage 2Thyroid carcinomaMedian agePlanned escalationTherapeutic optionsInhibitor exposure
2013
Vandetanib for aggressive and symptomatic medullary thyroid cancer
Deshpande H, Carling T, Khan N, Holt E. Vandetanib for aggressive and symptomatic medullary thyroid cancer. Journal Of Clinical Practice 2013, 10: 275-282. DOI: 10.2217/cpr.13.17.Peer-Reviewed Original ResearchMedullary thyroid cancerThyroid cancerSymptomatic medullary thyroid cancerMetastatic medullary thyroid cancerNew tyrosine kinase inhibitorsThyroid cancer accountsTyrosine kinase inhibitorsAggressive metastatic formsGrowth factor receptorProto-oncogene RETCancer accountsClinical trialsSignificant symptomsMetastatic formSporadic formsMalignant cellsUS FDAClinical useVandetanibKinase inhibitorsFactor receptorCancerFirst agentPhase IIDisease